Skip to content
Open access

Dynamic balance of CRISPR-Cas immunity and resistance plasmid anti-immunity mediated by a bifunctional protein AcrIE10

Aug 2026 · Nature Communications · Vol 17 · 0 citations · 49 references
Medicine

TL;DR

Molecular mechanisms by which AcrIE10 operates as a dual functionAcr-Aca protein to achieve a delicate balance between host CRISPR-Cas immunity and plasmid anti-defense are elucidated.

Abstract

Despite targeting by CRISPR-Cas system, antimicrobial resistance plasmids are prevalent in clinical isolates of carbapenem-resistant Klebsiella pneumoniae which represent a major public health threat. A stable co-existence of plasmids and CRISPR-Cas systems is mediated by anti-CRISPR (Acr) proteins. Here, we report that previously identified AcrIE10 encoded by a resistance plasmid combines two functions: it inhibits CRISPR immunity by directly binding Cas7* subunit through its Acr domain, and acts as an Acr-associated (Aca) protein that self-represses the transcription of Acr locus. AcrIE10 is an example of an Aca protein that utilizes N-terminal ribbon-helix-helix (RHH) domain to specifically recognize the inverted repeat (IR) region in its own promoter. Crucially, a dimerization of AcrIE10 dimers is required for the effective binding to the IR and self-repression, while stoichiometry-dependent interaction with Cas7* facilitates transition to de-repressed state. These findings elucidate molecular mechanisms by which AcrIE10 operates as a dual functionAcr-Aca protein to achieve a delicate balance between host CRISPR-Cas immunity and plasmid anti-defense. The transmission of plasmids represents a key mechanism for antimicrobial resistance. Here, authors show AcrIE10 inhibits bacterial CRISPR immunity and dynamically regulates self-expression, balancing host immunity and plasmid anti-defense.

Read PDF

Similar papers

#gene editing Aug 2026

CRISPR/Cas9-Mediated Site-Directed Mutagenesis of Genes in Klebsiella pneumoniae.

This protocol minimizes off-target editing, shortens experimental timelines, reduces screening workload, and provides a reliable platform for investigating resistance mechanisms, validating candidate genes, and supporting functional genomics studies in clinically relevant bacterial pathogens.

Chun Liu, Quan Zhang, Ke Ma · 0 citations
Open access Oct 2026

Acquisition of novel arrays via horizontal gene transfer rewires CRISPR-mediated defense in Pseudomonas aeruginosa

ABSTRACT Clustered regularly interspaced short palindromic repeat (CRISPR)-associated (Cas) systems form the adaptive immunity of prokaryotes, conferring sequence-specific protection against genetic parasites. Here, we functionally characterized the type I-F CRISPR-Cas system of Pseudomonas aeruginosa ATCC 10145 (PA101...

Robbie Paul P. Malaluan, R. L. Dy · 0 citations
#protein folding Open access Aug 2026

Structural insights into Cas9 inhibition by AcrIIA17 via bridge helix interaction

The crystal structure of AcrIIA17 is presented and its mechanism of Staphylococcus aureus Cas9 (SauCas9) inhibition is elucidated, identifying AcrIIA17 as an Acr protein that targets the Cas9 BH domain and reveal the BH domain as a regulatory checkpoint in Cas9 activation.

G. Kim, Hyo Been Jin, Yong-Jun Kang et al. · 0 citations
Review Open access Sep 2026

CRISPR-CAS GENOME EDITING AND MOLECULAR DIAGNOSTICS: EMERGING PERSPECTIVES IN GENETICS AND BIOCHEMICAL RESEARCH

Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and their associated (Cas) proteins have progressed from an obscure, unannotated repeat sequence first noted in Escherichia coli in 1987 to one of the most versatile toolkits in modern genetics and biochemistry. This chapter provides an expanded, detail...

P. M, R. Sathya, Gautham Suresh S. P et al. · 0 citations
#gene editing Review Open access Aug 2026

CRISPR gene therapy: a review

Clinical applicability is limited by issues such off-target effects, PAM sequence restrictions, DNA damage-induced toxicity, and immunological responses to Cas proteins, despite its wide therapeutic potential, but improvements in delivery methods and high-fidelity Cas9 variations are being addressed.

Sanjeyan N., G. G., H. S et al. · 0 citations
Open access Sep 2026

BaCas12a3 represents a new subtype of type V CRISPR effector with collateral activity toward tRNA

Abstract The CRISPR–Cas12 family encompasses diverse RNA-guided nucleases with both DNA- and RNA-targeting subtypes. They can trigger antiviral activities through either direct elimination of invading nucleic acids or activating broad collateral cleavage to induce abortive infection. Here, we report a novel type V CRIS...

Xin Li, Chen-Wei Wu, Jin-Shan Guo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.